How Hologic Stock Has Fared in the Last Month
After rising from $36.53 on April 9, 2018, to $42.91 on July 31, 2018, Hologic (HOLX) stock slid to $37.90 on October 29, 2018.
What Analysts Recommend for Hologic Stock
In November 2018, of the total 20 analysts covering Hologic (HOLX), ten analysts have given the stock a “buy” or higher rating, and ten analysts have given it a “hold” rating.
How Hologic’s Revenue Is Trending
For fiscal 2019 and 2020, Hologic (HOLX) is expected to generate total revenues of $3.32 billion and $3.45 billion, respectively.
Cynosure Headwinds Trigger Analyst Downgrades on HOLX Stock
As of September 18, ten of the 19 analysts that cover HOLX stock gave the company a “buy” or “strong buy” recommendation.
Hologic’s Cynosure Headwinds Could Impact 2018 Earnings
On September 12, Hologic (HOLX) provided an update on the financial impact of the suspension of its marketing and distribution of the company’s Vitalia handpieces and probes.
A Look at Hologic Stock’s Recent Performance
Currently, HOLX stock is trading lower than its 50-day moving average of $39.80 but higher than its 200-day moving average of $39.16.
How Hologic’s Valuation Stacks Up with Peers
The company has delivered a robust financial performance in recent quarters. However, the stock has been on a bearish trend during the recent period.
Hologic Stock Down ~9% Year-to-Date
On September 6, Hologic (HOLX) ended the day at $38.74.
Analysts Still Bullish on Teleflex Stock
Teleflex’s (TFX) interest expenses increased from $19.89 million in the second quarter of 2017 to $26.65 million in the second quarter of 2018.
How Is Roche’s Diagnostics Segments Positioned in August?
Roche’s tissue diagnostics unit generated revenues of 290.0 million Swiss francs in the second quarter, reflecting ~15% YoY growth at CER.
Hologic’s GYN Surgical Business Grew in Fiscal Q3 2018
In the fiscal third quarter, NovaSure witnessed a YoY revenue decline of 7.6%.
Diagnostics Business Emerges as a Key Growth Driver in Fiscal Q3
In fiscal Q3 2018, Hologic (HOLX) reported revenues of ~$294.3 million for its Diagnostics segment.
A Look at Hologic’s Acquisition of Faxitron Bioptics
In the fiscal third quarter, Hologic reported revenues of ~$307.9 million for its biggest business, Breast Health.
Analysts’ Recommendations for Hologic and Its Peers in August
Of the 19 analysts covering Hologic (HOLX) in August, five rated it as a “strong buy,” and seven rated it as a “buy.”
What to Expect from Hologic’s Fiscal Third-Quarter Results
In the third quarter of 2018, Wall Street analysts estimate Hologic will register adjusted EPS of $0.56, a YoY increase of ~11.9%.
Hologic Stock Falls Over 9% on 2Q18 Results, Lower 2018 Guidance
Yesterday, after the market closed, Hologic (HOLX) released its 2Q18 earnings results for the quarter that ended on March 31.
Can HOLX Stock Rebound from Its Recent Lows?
On March 28, 2018, Hologic (HOLX) stock ended trading at a closing price of $37.39.
Wall Street Largely Bullish on Hologic Stock in March
Of the 20 brokerage firms covering HOLX stock, 75% of them have a “buy” or “strong buy” recommendation for the stock.
Hologic and Dexalytics Partner to Develop Software for Athletes
On February 22, 2018, Hologic (HOLX) announced it has entered into an agreement with the University of Minnesota as the exclusive provider of Dexalytics: Teams.
Philips and Hologic Partners in Women’s Health Area
On March 2, 2018, Hologic (HOLX) announced a global partnership with Royal Philips (PHG) to provide an integrated health solution for women.
Hologic Gets FDA Approval for Its New 3D Imaging Technology
On March 27, Hologic (HOLX) announced that the FDA has approved its Clarity HD high-resolution 3D imaging and Intelligent 2D imaging.
Why Mizuho Securities Upgraded Teva Pharmaceutical to a ‘Buy’
On January 9, 2018, Mizuho Securities upgraded Teva Pharmaceutical Industries (TEVA) from a “neutral” to a “buy” rating. It came after Teva announced its business restructuring plan.
Can Edwards Lifesciences See Robust Net Profit Margin in 2017?
In its 2Q17 earnings conference call, Edwards Lifesciences (EW) projected 2017 adjusted EPS to fall to $3.65–$3.85, which is higher than the previous $3.43–$3.55.
Inside Abiomed’s Profit Margin Expectations for Fiscal 2018
For fiscal 2018 (ended March 31, 2018), Abiomed (ABMD) has projected that its operating margins will be in the range of 22%–24%.
Baxter Expected to Report Robust Revenue Growth in 2017
Baxter International (BAX) has projected its YoY (year-over-year) revenue growth for 2017 at 1.0%–2.0% on a reported basis.
Does Novartis See Much Potential for Its Surgical Business?
In 2017, Novartis (NVS) has planned to conduct a review of its Alcon segment to evaluate the business’s growth potential.
Philips Introduces New Imaging and Treatment Planning Solutions
Koninklijke Philips (PHG) has a market cap of $28.0 billion. It fell 1.1% to close at $29.44 per share on September 26.
Philips Acquires PathXL to Expand Its Business
Koninklijke Philips (PHG) has a market cap of $24.5 billion. It rose by 1.8% and closed at $26.15 per share on June 21, 2016.
How Are IHI’s Holdings’ Moving Averages Trending?
IHI has 47 stocks in its portfolio. As of June 9, 2016, 94% of IHI’s stocks were trading above their 20-day moving averages.
Philips Announced the Pricing of Its Lighting IPO
Koninklijke Philips (PHG) raised 750 million euros ($839 million) from its initial public offering (or IPO) of its Lighting business.
Exane BNP Paribas Upgrades Koninklijke Philips to ‘Outperform’
Koninklijke Philips (PHG) has a market cap of $24.7 billion. It fell by 0.94% to close at $26.48 per share on May 11, 2016.
Koninklijke Philips Reported Mixed Quarterly Results for 1Q16
Koninklijke Philips (PHG) has a market cap of $25.4 billion. PHG fell by 4.2% to close at $27.09 per share on April 25, 2016.
Boston Scientific Led IHI’s Large Caps
Boston Scientific (BSX) rose 1.5% as of November 6, 2015. The stock closed at $18.94 and was trading above its 20-day, 50-day, and 100-day moving averages.
How Does Acuity Brands Compare to Its Peers?
Acuity Brands is way ahead of its competitors based on gross profit margin, EPS, and current, PE, and PBV ratios.
Cooper Companies Reported Mixed 2Q15 Results
Cooper Companies (COO) is a $7.33 billion global medical device company. The company has two business units, CooperVision and CooperSurgical.
Outflows Continue in High-Yield Bond Funds: Week to June 19
Last week, investor flows in high-yield bond funds remained in negative territory for the second week in a row. They’ve witnessed inflows of $2.6 billion YTD.
Assessing Relational Investors’ holdings in fourth quarter
This article discusses Relational Investors’ holdings for the fourth quarter of 2014.
Apple expands its capital return program: Is the stock undervalued?
Apple announced an increase in the size of its capital return program by an addition of $30 billion for a total program size of over $130 billion.